Department of Radiation Oncology, NewYork-Presbyterian/Weill Cornell Medicine, New York, NY, USA.
Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Curr Oncol Rep. 2020 Nov 19;23(1):4. doi: 10.1007/s11912-020-00993-w.
Positive results from recent immunotherapy trials of non-small cell lung cancer (NSCLC) have coincided with a greater appreciation for the impact of radiation therapy (RT) on tumor immunity. Here, we summarize key clinical findings and ongoing efforts to combine immunotherapy and RT for the treatment of NSCLC.
The role of immunotherapy for NSCLC has expanded significantly following the pivotal approvals of nivolumab and pembrolizumab for metastatic NSCLC, maintenance durvalumab in unresectable stage III NSCLC, and atezolizumab for metastatic NSCLC. Several small early-phase trials have demonstrated the ability of RT to elicit clinically significant tumor immunity. These positive findings support current trial efforts combining RT with immunotherapy for NSCLC. Recently initiated trials of RT and immunotherapy hold significant promise in expanding the therapeutic options for NSCLC. Optimization of therapy will require careful patient selection to yield meaningful improvements in clinical outcomes.
最近非小细胞肺癌（NSCLC）免疫治疗试验的阳性结果与人们对放射治疗（RT）对肿瘤免疫影响的认识不断提高同时出现。在此，我们总结了将免疫治疗与 RT 联合用于 NSCLC 治疗的关键临床发现和正在进行的努力。
纳武单抗和派姆单抗获批用于转移性 NSCLC、不可切除 III 期 NSCLC 中维持durvalumab以及阿替利珠单抗获批用于转移性 NSCLC 后，免疫治疗在 NSCLC 中的作用显著扩大。几项小型早期阶段试验已经证明 RT 能够引发具有临床意义的肿瘤免疫。这些积极的发现支持目前将 RT 与免疫治疗联合用于 NSCLC 的试验努力。最近启动的 RT 和免疫治疗试验在为 NSCLC 提供更多治疗选择方面具有很大的希望。为了获得临床结局的有意义改善，需要对患者进行仔细选择以优化治疗。
